At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-label, Single-arm Trial of Trastuzumab Deruxtecan (DS 8201a) in HER2-positive, Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-containing Regimen (DESTINY-Gastric02)
In Brief
A Phase 2 clinical trial evaluating Trastuzumab deruxtecan for Adenocarcinoma Gastric Stage IV With Metastases and Adenocarcinoma - GEJ. Completed, enrolled 79 participants across 37 sites in 5 countries.
Detailed Summary
This study will find out if trastuzumab deruxtecan is safe and works for participants with gastric or gastroesophageal junction cancer. They must have human epidermal growth factor receptor 2 (HER2)-positive gastric or gastro-esophageal junction (GEJ) cancer: * that cannot be removed surgically * that has moved to other parts of the body * that got worse during or after treatment that included trastuzumab The study will enroll about 80 participants. Sites will be in North America and the European Union.
Study Details
Timeline
Interventions
Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion